Evidence map›Paper›PMID 33690610›Full record

ArticlePloS one2021

Effects of the Pratt pouch model of dispensing nevirapine prophylaxis on HIV exposed infant completion of 6 weeks of prophylaxis in Uganda.

Edward Bitarakwate, Kim Ashburn, Patrick Kazooba, Ronald Khamasi, Eliab Natumanya, Nicole Herrera, Boaz Owomugisha, Robert A Malkin, Linda Kisaakye

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Edward BitarakwateElizabeth Glaser Pediatric AIDS Foundation (EGPAF), Kampala, Uganda.
Kim AshburnElizabeth Glaser Pediatric AIDS Foundation, Washington, DC, United States of America.ORCID 0000-0002-4936-5073
Patrick KazoobaElizabeth Glaser Pediatric AIDS Foundation (EGPAF), Kampala, Uganda.
Ronald KhamasiElizabeth Glaser Pediatric AIDS Foundation (EGPAF), Kampala, Uganda.
Eliab NatumanyaElizabeth Glaser Pediatric AIDS Foundation (EGPAF), Kampala, Uganda.
Nicole HerreraElizabeth Glaser Pediatric AIDS Foundation, Washington, DC, United States of America.
Boaz OwomugishaElizabeth Glaser Pediatric AIDS Foundation (EGPAF), Kampala, Uganda.
Robert A MalkinBiomedical Engineering, Duke University, Durham, North Carolina, United States of America.
Linda KisaakyeUganda Ministry of Health, Kampala, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe innovative Pratt pouch could optimize dispensing nevirapine prophylaxis to HIV-exposed infants in pre-measured single dose pouches to increase completion of the full 6 week infant nevirapine regimen. MATERIALS AND

methodsNineteen health facilities with highest HIV positivity rates among pregnant women across 9 districts in southwest and central Uganda were assigned to control and intervention groups. HIV-positive women enrolled at intervention facilities received pouches filled with premeasured single doses of nevirapine using Uganda national guidelines, which were integrated into the existing drug distribution system. During antenatal care (ANC) women received 14 pouches to cover time until the 6 day postpartum visit, with an additional 8 pouches if women were delayed in returning to the facility, and 28 pouches after delivery. Women enrolled at control facilities received standard nevirapine syrup following delivery for postnatal infant prophylaxis. In a select number of intervention facilities, during ANC, women received all 42 pouches needed to complete the 6 weeks regimen. Medical record data from enrolled women were extracted; interviews with HIV-positive women during postnatal care visits were conducted. Data were collected January to August 2018 (control sites) and October 2019 to February 2020 (intervention sites). Unadjusted and adjusted logistic regression models were used to identify factors associated with facility delivery, postnatal care follow-up visit, and completion of the full 6 weeks infant nevirapine regimen.

resultsSignificantly more women in the intervention (n = 320) versus control (n = 340) group had facility delivery (292/316, 92.4% versus 169/340, 49.7%, p<0.0001), postnatal visits within 2 weeks postpartum (295/297, 99.3% versus 133/340, 39.1%, p<0.0001) and reported their infants completing the full 6 weeks infant prophylaxis regimen (299/313, 95.5% versus 210/242, 86.8%, p = 0.0002). Dispensing 42 versus 14 pouches during ANC did not have negative effects on these outcomes. Among out-of-facility deliveries, a higher proportion of infants received nevirapine within 72 hours of birth in the intervention versus control group, 95.8% versus 77.9%. In multivariate models, the intervention group was the only significant factor associated with facility delivery or completion of the full 6 weeks infant prophylaxis.

conclusionsUse of the Pratt pouch resulted in an increase in HIV-exposed infants completing the full 6weeks prophylaxis regimen and associated benefits including increasing facility delivery and women's adherence to postnatal care services.

Indexed as

AdultAnti-HIV AgentsDrug ImplantsDrug PackagingFemaleHIV InfectionsHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalNevirapinePostnatal CarePregnancyPregnancy Complications, InfectiousRetrospective StudiesSurveys and QuestionnairesAnti-HIV AgentsDrug ImplantsNevirapine

Identifiers

PMID33690610
PMCPMC7946283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.